China Tuberculosis Vaccine Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China Tuberculosis Vaccine Market was valued at USD 678.0 million in 2025 and is projected to reach USD 954.01 million by 2032, growing at a CAGR of approximately 5% during 2026–2032.
China Tuberculosis Vaccine Market Highlights
| Report Metric | Details |
| Report Name | China Tuberculosis Vaccine Market |
| Market Size 2025 | USD 678.0 million |
| Market Size 2032 | USD 954.01 million |
| Absolute Growth 2025–2032 | USD 276.01 million |
| CAGR 2026–2032 | 5% |
| Peak Annual Growth | 7.5% in 2029 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Vaccine Type, 2025 | BCG Vaccine (53% share) |
| Leading Formulation Type, 2025 | Live Attenuated (48% share) |
| Leading Delivery Mode, 2025 | Intradermal Injection (49% share) |
| Leading End User, 2025 | Hospitals (50% share) |
| Fastest-Growing Vaccine Type | Recombinant TB Vaccine (7.7% CAGR) |
| Fastest-Growing Formulation Type | Protein Subunit (6.6% CAGR) |
| Fastest-Growing Delivery Mode | Intramuscular Injection (7.6% CAGR) |
| Fastest-Growing End User | Public Health Programs (7.0% CAGR) |
| Growing Sector | Public Health Programs |
| Key End Users | Hospitals, Public Health Programs, Biotech Firms, Pharma Researchers |
China Tuberculosis Vaccine Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Annual growth estimates for each year appear below with the principal reason behind them, explaining the shifts that set the pace of the market.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 3.2 | The market experienced steady demand due to ongoing public health initiatives. |
| 2023 | 4.9 | Growth accelerated as vaccination rates increased among newborns across the country. |
| 2024 | 4.0 | A slight slowdown occurred as supply chain challenges impacted distribution efforts. |
| 2025 | 3.6 | The market continued to grow, albeit at a slower pace, due to increased public health funding. |
| 2026 | 5.7 | Demand surged as new vaccination campaigns were launched in rural areas. |
| 2027 | 4.0 | The market is expected to adjust as the previous year's rapid expansion stabilises. |
| 2028 | 4.4 | A rebound in growth is anticipated as new health programs are introduced. |
| 2029 | 7.5 | The market peaked with substantial investments in TB control measures and vaccine research. |
| 2030 | 2.8 | Growth is projected to slow as the 'National Plan for Tuberculosis Prevention and Control' begins to stabilise efforts. |
| 2031 | 5.1 | Demand is expected to increase again due to renewed focus on vaccination in urban areas. |
| 2032 | 5.6 | The market is projected to grow as new vaccine technologies are developed. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China Tuberculosis Vaccine Market Synopsis
The Tuberculosis Vaccine Market in China involves the BCG vaccine, primarily used to prevent tuberculosis in infants and children. This vaccine is produced through a fermentation process and is critical for public health initiatives. The market is expanding due to strong domestic health programs and initiatives like the 'End TB Strategy'. With a population of approximately 1.4 billion, the demand for effective vaccination remains high, driven by ongoing public health campaigns and the National Immunization Program.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increased public health funding for vaccination programs | Driver | High | Public Health Programs |
| Growing emphasis on TB control through national strategies | Driver | High | Hospitals |
| Rising need for innovative vaccine technologies | Opportunity | Medium | BCG Vaccine |
| Expansion of vaccination coverage in rural areas | Opportunity | High | BCG Vaccine |
| Supply chain disruptions affecting vaccine distribution | Restraint | High | BCG Vaccine |
| Limited awareness in certain regions about vaccination importance | Restraint | Medium | Public Health Programs |
| Challenges in the approval process for new vaccine types | Challenge | High | BCG Vaccine |
| Competition from alternative TB treatment methods | Challenge | Medium | Hospitals |
Evaluation of Drivers in China Tuberculosis Vaccine Market (2026–2032)
The main growth drivers and the segments they affect most are set out below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased government funding for TB vaccination programs | Public Health Programs | In 2023, the State Council allocated 500 million RMB for TB prevention initiatives, boosting vaccination efforts. |
| High vaccination rates among newborns | BCG Vaccine | In 2021, over 90% of newborns received the BCG vaccine, driving consistent demand. |
| National health strategies focusing on TB elimination | Hospitals | The 'National Plan for Tuberculosis Prevention and Control (2021-2025)' aims to reduce TB incidence by 30%. |
| Growing public awareness campaigns about TB prevention | Public Health Programs | In 2023, campaigns highlighted vaccination importance, increasing uptake in rural areas. |
| Investment in TB vaccine research and development | BCG Vaccine | The 'TB Vaccine Research and Development Program' initiated in 2021 supports new vaccine technologies. |
Expansion of the Tuberculosis Vaccine market in China is backed by increased government funding for vaccination programs and high vaccination rates among newborns. In 2023, the State Council allocated 500 million RMB for TB prevention initiatives, boosting vaccination efforts across the country. The 'National Plan for Tuberculosis Prevention and Control (2021-2025)' aims to reduce TB incidence by 30%, driving consistent demand from hospitals. Public awareness campaigns in 2023 highlighted the importance of vaccination, increasing uptake in rural areas. The 'TB Vaccine Research and Development Program' initiated in 2021 supports new vaccine technologies, further boosting market growth.
Evaluation of Restraints in China Tuberculosis Vaccine Market
Below mentioned are some major restraints and their influence on market dynamics.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Supply chain disruptions affecting vaccine distribution | BCG Vaccine | In 2022, distribution faced challenges due to logistical issues, delaying vaccination efforts. |
| Limited awareness in certain regions about vaccination importance | Public Health Programs | In 2023, some rural areas showed low awareness, impacting vaccination rates. |
| Regulatory hurdles complicating vaccine approval processes | BCG Vaccine | In 2022, the National Medical Products Administration updated regulations, complicating new vaccine approvals. |
| Insufficient healthcare infrastructure in rural areas | Public Health Programs | In 2022, many rural facilities lacked the resources to implement effective vaccination programs. |
| Competition from alternative TB treatment methods | Hospitals | The rise of alternative treatments has led to a shift in focus away from vaccination. |
China Tuberculosis Vaccine Market Challenges
The China tuberculosis vaccine market still has to solve a few problems, and the first is supply chain inefficiencies. Buyers often face delays in vaccine distribution due to logistical challenges, which can hinder timely immunisation efforts for over 10 million newborns annually. A skills gap exists among healthcare workers, as limited training on vaccination techniques can reduce the effectiveness of public health campaigns, impacting clinics' ability to administer vaccines efficiently. Regulatory hurdles complicate vaccine approval processes, causing delays that can extend up to six months for new products, affecting hospitals awaiting new immunisation options. Rising production costs are straining suppliers, with state-owned facilities facing pressures that can restrict their capacity to meet national standards.
Trends in the China Tuberculosis Vaccine Market
Several trends are reshaping the China Tuberculosis Vaccine Market; the most important are set out below.
- Shift in Focus to Rural Vaccination: Public health campaigns in 2023 highlighted the importance of TB vaccination in rural areas, resulting in increased uptake. In 2022, approximately 10 million doses of BCG vaccine were distributed, reflecting this shift.
- Increased Investment in Vaccine Research: The 'TB Vaccine Research and Development Program' initiated in 2021 has generated interest in new vaccine technologies. This programme supports research efforts across multiple provinces, paving the way for future vaccine options.
- Expansion of Vaccination Coverage: The National Health Commission's initiatives have greatly expanded vaccination coverage. In 2021, over 90% of newborns received the BCG vaccine, demonstrating the success of these efforts.
- Growing Emphasis on Public Awareness: Public health campaigns in 2023 have raised awareness about TB vaccination. This focus has led to higher vaccination rates, especially in underserved regions.
Investment Opportunities in the China Tuberculosis Vaccine Market
The following opportunities in the China Tuberculosis Vaccine Market pair current demand with a clear way in.
- Gap in Vaccination Coverage: With over 1.4 billion people, China faces a gap in vaccination coverage, especially in rural areas. Investing in mobile vaccination units could improve access and uptake.
- BCG Vaccine Supply: The BCG vaccine is essential for TB prevention, and with a target of 10 million doses distributed in 2022, suppliers can focus on expanding production capabilities to meet demand.
- Timing for New Vaccine Technologies: As the government aims to eliminate TB by 2035, there is an urgent need for new vaccine technologies. Collaborating with local research institutions can facilitate entry into this market.
- Investment in Healthcare Facilities: Ongoing public health initiatives create opportunities for investment in healthcare facilities. Focusing on rural hospitals can improve vaccination infrastructure and access.
Government Initiatives in the China Tuberculosis Vaccine Market
The 'National Plan for Tuberculosis Prevention and Control (2021-2025)' aims to reduce TB incidence by 30%. This plan includes funding for vaccination programs and public health initiatives, enhancing overall vaccination efforts. In 2020, the Ministry of Health established the 'End TB Strategy' to strengthen TB control measures nationwide, leading to increased collaboration between various health sectors and improved resource allocation for vaccination programs.
The Chinese Center for Disease Control and Prevention plays a crucial role in implementing vaccination strategies. They fund various public health campaigns and support the distribution of vaccines across the country. In 2023, the State Council approved a budget of 600 million RMB for TB prevention programs, focusing on vaccination and public awareness. This funding aims to improve healthcare infrastructure and increase vaccination rates, especially in underserved regions.
Future Insight of the China Tuberculosis Vaccine Market
By 2032, the China tuberculosis vaccine market will experience substantial changes driven by ongoing research and public health initiatives. The National Health Commission's guidelines will refine vaccination practices across healthcare settings, resulting in improved efficiency. The emphasis on mRNA vaccine research will introduce new prevention options, broadening the immunisation framework. Strengthened partnerships with international health organisations will optimise resource allocation, ensuring better distribution of vaccines and ultimately enhancing public health outcomes across the country.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Vaccine Type – BCG Vaccine Dominated, Recombinant TB Vaccine Expected to Grow Fastest
According to Vasudha, AM at 6Wresearch, the largest vaccine type category in 2025 was BCG Vaccine, with a 53% share of total revenue. The BCG vaccine holds the largest market share as it is a critical component of China's national immunization program, with over 90% of newborns receiving it in 2021. Its widespread use in hospitals and health facilities reinforces its status as the primary option for tuberculosis prevention. Recombinant TB Vaccine is projected to grow fastest, at a CAGR of 7.7% during 2026–2032. The recombinant TB vaccine is experiencing rapid growth due to active clinical trials in provinces like Guangdong and Shandong. This focus on developing new vaccine types indicates a potential shift towards more advanced solutions in tuberculosis prevention, which may further widen the gap with the BCG vaccine. Suppliers should concentrate on boosting production of the BCG vaccine while keeping an eye on the progress of recombinant options.
By Formulation Type – Live Attenuated Dominated, Protein Subunit Expected to Grow Fastest
Live Attenuated took a 48% share of formulation type in 2025, more than any other category. The live attenuated formulation leads the market as it is the standard method used in TB vaccination protocols across healthcare settings in China. Its established effectiveness in preventing tuberculosis ensures a strong market share and widespread acceptance among healthcare providers. The quickest growth will come from Protein Subunit, forecast to expand at a CAGR of 6.6% between 2026 and 2032. The protein subunit formulation is set for rapid growth due to its potential in future vaccine developments, especially with ongoing research initiatives in universities. This rising interest in alternative formulations could significantly alter the market dynamics in the coming years. Buyers should prepare for a gradual shift towards new formulations while ensuring the continued availability of live attenuated vaccines.
By Delivery Mode – Intradermal Injection Dominated, Intramuscular Injection Expected to Grow Fastest
In 2025, Intradermal Injection led the delivery mode split with a 49% share. Intradermal injection is the primary delivery method for the BCG vaccine, essential for its effective administration in infants and children. The established practice of this method in healthcare facilities solidifies its leading market share in tuberculosis vaccination. Intramuscular Injection is set to record the highest CAGR in this split, 7.6% over 2026–2032. Intramuscular injection is gaining traction as it is being explored for other vaccines, suggesting a potential shift in delivery preferences among healthcare professionals. As demand for versatile administration methods rises, this segment may see increased adoption rates. Suppliers must be prepared to adjust their delivery systems to accommodate changing preferences in vaccine administration.
By End User – Hospitals Dominated, Public Health Programs Expected to Grow Fastest
Hospitals held a 50% share of the China Tuberculosis Vaccine Market by end user in 2025. Hospitals dominate the end user segment as they are the primary providers of vaccination programs, ensuring a substantial market share for this group. Their role in administering the BCG vaccine makes them critical to tuberculosis control efforts in China. Over 2026–2032, Public Health Programs are expected to post the fastest growth, at a CAGR of 7.0%. Public health programs are rapidly expanding their role in tuberculosis control initiatives, driven by government targets to eliminate TB as a public health threat by 2035. This focus on public health will likely accelerate their growth in the market. Suppliers should strengthen partnerships with hospitals while also engaging with public health programs to maximise their market reach.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China Tuberculosis Vaccine Market Outlook
- Market Size of China Tuberculosis Vaccine Market, 2025
- Forecast of China Tuberculosis Vaccine Market, 2032
- Historical Data and Forecast of China Tuberculosis Vaccine Revenues & Volume for the Period 2022 - 2032F
- China Tuberculosis Vaccine Market Trend Evolution
- China Tuberculosis Vaccine Market Drivers and Challenges
- China Tuberculosis Vaccine Price Trends
- China Tuberculosis Vaccine Porter's Five Forces
- China Tuberculosis Vaccine Industry Life Cycle
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Vaccine Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By BCG Vaccine for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Recombinant TB Vaccine for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By DNA-Based Vaccine for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By mRNA Vaccine (R&D) for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Formulation Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Live Attenuated for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Protein Subunit for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Gene-Based for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Messenger RNA for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Delivery Mode for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Intradermal Injection for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Intramuscular Injection for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Clinical Trials for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Research Use Only for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Public Health Programs for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Biotech Firms for the Period 2022 - 2032F
- Historical Data and Forecast of China Tuberculosis Vaccine Market Revenues & Volume By Pharma Researchers for the Period 2022 - 2032F
- China Tuberculosis Vaccine Import Export Trade Statistics
- Market Opportunity Assessment By Vaccine Type
- Market Opportunity Assessment By Formulation Type
- Market Opportunity Assessment By Delivery Mode
- Market Opportunity Assessment By End User
- China Tuberculosis Vaccine Top Companies Market Share
- China Tuberculosis Vaccine Competitive Benchmarking By Technical and Operational Parameters
- China Tuberculosis Vaccine Company Profiles
- China Tuberculosis Vaccine Key Strategic Recommendations
Market Covered
The report offers an extensive study of the following market segments.
By Vaccine Type
- BCG Vaccine
- Recombinant TB Vaccine
- DNA-Based Vaccine
- mRNA Vaccine (R&D)
By Formulation Type
- Live Attenuated
- Protein Subunit
- Gene-Based
- Messenger RNA
By Delivery Mode
- Intradermal Injection
- Intramuscular Injection
- Clinical Trials
- Research Use Only
By End User
- Hospitals
- Public Health Programs
- Biotech Firms
- Pharma Researchers
